Findings

What do systematic reviews say?

4,771 questions · 10,185 findings · 893 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,109 · 20.7%GRADE not reported 1,125 · 11%Very low 2,279 · 22.4%Low 2,514 · 24.7%Moderate 1,709 · 16.8%High 449 · 4.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Stem cell therapy vs control

Health‐related quality of life · DCM (non‐ischaemic)

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 272 participants
Very low

Stem cell therapy vs control

Functional capacityAssessed: 6MWT · DCM (non‐ischaemic)

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 230 participants
Very low

Stem cell therapy vs control

Performance status – change in functional class (NYHA) · DCM (non‐ischaemic)

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 398 participants
Low

Stem cell therapy vs control

MACE · DCM (non‐ischaemic)

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Stem cell therapy vs control

Ventricular arrhythmias (within 30 days) · DCM (non‐ischaemic)

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 504 participants
Low

Anti‐EGFR therapy vs placebo or usual care

Overall survival ‐ first‐line studies · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in overall survival ‐ first‐line studies compared with placebo or standard of care (moderate certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
HR 0.89 [0.76, 1.04]
3 studies · 1000 participants
Moderate

Anti‐EGFR therapy vs placebo or usual care

Overall survival ‐ recurrent disease studies · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in overall survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
HR 0.79 [0.51, 1.21]
4 studies · 489 participants
Low

Anti‐EGFR therapy vs placebo or usual care

Lymphopenia · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in lymphopenia compared with placebo or standard of care (low certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
OR 0.97 [0.19, 4.81]
4 studies · 1146 participants
Low

Anti‐EGFR therapy vs placebo or usual care

Neutropenia · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in neutropenia compared with placebo or standard of care (low certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
OR 1.29 [0.82, 2.03]
4 studies · 1146 participants
Low

Anti‐EGFR therapy vs placebo or usual care

Thrombocytopenia · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in thrombocytopenia compared with placebo or standard of care (low certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
OR 3.69 [0.51, 26.51]
4 studies · 1146 participants
Low

Anti‐EGFR therapy vs placebo or usual care

Progression‐free survival · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in progression‐free survival ‐ first‐line studies compared with placebo or standard of care (low certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
HR 0.94 [0.81, 1.1]
2 studies · 894 participants
Low

Anti‐EGFR therapy vs placebo or usual care

Progression‐free survival ‐ recurrent disease studies · glioblastoma in adults

Anti‐EGFR therapy may leads to lower progression‐free survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
HR 0.75 [0.58, 0.96]
3 studies · 275 participants
Low

Psychological therapy vs any non‐therapy comparator: end‐of‐intervention and short‐term follow‐up

Depressive symptomatology (lower = less depressive symptomatology): end‐of‐intervention · older people with depression

1 finding from 1 review

Psychological therapies for depression in older adults residing in long‐term care settings 2024 · Cochrane Headline outcomes only
no estimate extracted
18 studies · 644 participants
Very low

Psychological therapy vs any non‐therapy comparator: end‐of‐intervention and short‐term follow‐up

Treatment non‐acceptability (higher = greater non‐acceptability): end‐of‐intervention · older people with depression

1 finding from 1 review

Psychological therapies for depression in older adults residing in long‐term care settings 2024 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 313 participants
Very low

Psychological therapy vs any non‐therapy comparator: end‐of‐intervention and short‐term follow‐up

Depression remission · older people with depression

1 finding from 1 review

Psychological therapies for depression in older adults residing in long‐term care settings 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 82 participants
Very low

Psychological therapy vs any non‐therapy comparator: end‐of‐intervention and short‐term follow‐up

Quality of life or psychological well‐being (higher = higher quality of life or psychological well‐being): end‐of‐intervention · older people with depression

1 finding from 1 review

Psychological therapies for depression in older adults residing in long‐term care settings 2024 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 195 participants
Very low

Psychological therapy vs any non‐therapy comparator: end‐of‐intervention and short‐term follow‐up

Anxious symptomatology (lower = less anxious symptomatology): end‐of‐intervention · older people with depression

1 finding from 1 review

Psychological therapies for depression in older adults residing in long‐term care settings 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 115 participants
Very low

Surgery plus radiotherapy vs Radiotherapy alone

Locoregional recurrence · Adults with oral cavity or oropharyngeal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment 2023 · Cochrane All outcomes
Locoregional recurrence: not reported.
0 studies
No studies found

Surgery plus radiotherapy vs Radiotherapy alone

Total mortality · Adults with oral cavity or oropharyngeal cancer

It is very uncertain whether surgery plus radiotherapy changes total mortality compared with radiotherapy alone (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment 2023 · Cochrane All outcomes
3 years
HR 0.24 [0.10, 0.59]
1 study · 35 participants
Very low

Surgery plus radiotherapy vs Radiotherapy alone

Disease-free survival · Adults with oral cavity or oropharyngeal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment 2023 · Cochrane All outcomes
Disease-free survival: not reported.
0 studies
No studies found